India Launches Generic Semaglutide at $14 Monthly This Weekend

50 Generic Brands Expected in India

About 50 generic semaglutide brands are expected to enter the Indian market alone, some launching as early as this weekend. This marks the beginning of the global generic GLP-1 era, with India leading the way in affordable access to these medications.

The Indian launch comes after Novo Nordisk's semaglutide patent protections expired in that country, similar to what occurred in Canada on January 4, 2026. However, India's regulatory approval process moved faster than Canada's system, allowing generic manufacturers to reach market first.

Canadian Applications Still Under Review

While Canada was the first country globally to lose patent protection for semaglutide in January, Health Canada has not yet approved any generic versions. The agency is currently reviewing nine generic semaglutide applications under its 180-day priority review timeline.

Companies with applications under Health Canada review include:

• Sandoz Canada
• Apotex Inc.
• Teva Canada
• Taro Pharmaceuticals
• Aspen Pharmacare
• Vimy Pharma (expected to file in coming weeks)

Most Canadian generic launches are anticipated for mid to late 2026, pending Health Canada approvals.

Global Price Comparison Context

The $14 monthly pricing in India represents a dramatic reduction from current Canadian brand-name costs. Ozempic currently costs between $200-$300 monthly at Canadian pharmacies, while Wegovy ranges from $300-$400 monthly depending on the pharmacy and dosage strength.

Canadian experts have projected generic semaglutide could cost approximately 35% of brand-name prices when launched domestically, though final pricing will depend on provincial negotiations and pharmacy markups.

Manufacturing and Supply Chain Implications

The Indian market launch demonstrates the global manufacturing capacity now coming online for generic semaglutide production. Multiple Indian pharmaceutical companies have invested in the complex manufacturing processes required to produce these medications at scale.

In Canada, domestic manufacturing is also being established, with Vimy Pharma planning Canadian-made generic semaglutide production as part of its Health Canada application strategy.

Coverage Considerations

The availability of low-cost generic alternatives internationally may influence Canadian provincial drug plan decisions. Most provinces have indicated they are waiting for Health Canada approvals before establishing coverage policies for generic semaglutide medications.

Canadian employers and private insurers are also monitoring generic developments closely, as current brand-name costs have strained drug benefit budgets. The insurance coverage landscape may shift significantly once generics become available domestically.

Regulatory Timeline Updates

Health Canada's 180-day priority review process for generic GLP-1 applications represents one of the fastest regulatory timelines globally. The agency has committed to completing reviews by mid-2026 for most applications currently under assessment.

Canadians can track the latest developments through our frequently updated FAQ section, which includes current application statuses and expected launch timelines for each generic manufacturer.